Skip to main content
Pharmicell Co.,Ltd. logo

Pharmicell Co.,Ltd. — Investor Relations & Filings

Ticker · 005690 ISIN · KR7005690003 KO Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2024-03-20 Annual Report
Country KR South Korea
Listing KO 005690

About Pharmicell Co.,Ltd.

https://www.pharmicell.com/eng/

Pharmicell Co., Ltd. is a biopharmaceutical company specializing in stem cell technology and advanced bio-based materials. The company is a pioneer in regenerative medicine, having developed Hearticellgram-AMI, the world's first approved stem cell therapy for acute myocardial infarction. Its core business includes the development of stem cell therapeutics, a stem cell banking service for adult and cord blood cells, and a line of cosmetics based on stem cell culture media. A significant division focuses on fine chemicals, manufacturing and supplying critical raw materials for the pharmaceutical industry, such as nucleosides, mPEGs, and oligonucleotides for gene therapies. The company also produces eco-friendly flame retardants for industrial use.

Recent filings

Filing Released Lang Actions
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for Pharmicell Co., Ltd. for the 56th fiscal year (2023). It contains comprehensive financial data, management discussion, business overview, and corporate governance details, which corresponds to the definition of an Annual Report (10-K). FY 2023
2024-03-20 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy) and is filed by a shareholder (Riphan Asset Management) to solicit votes against the incumbent management's director candidates at the upcoming Annual General Meeting. This is a classic proxy solicitation document used to request shareholder support for specific voting outcomes, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-03-07 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in shareholding and collateral agreements by a major shareholder (Kim Hyun Soo) of Pharmicell Co., Ltd. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2024-02-29 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Pharmicell Co., Ltd. It contains the agenda for the upcoming annual general meeting, including the approval of financial statements, election of directors, and remuneration limits. It also includes management's business overview and financial data (balance sheet, income statement, etc.) as reference materials for shareholders. This type of document is standard for proxy solicitation and providing information to shareholders ahead of a meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2024-02-27 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (often filed under the DART system) used to provide shareholders with information regarding upcoming general meetings, including agenda items like financial statement approval, director appointments, and remuneration limits. This document is specifically designed to solicit proxies for the 56th Annual General Meeting. While it contains financial data, it is not an Annual Report (10-K) or an Earnings Release (ER), but rather a proxy solicitation document.
2024-02-27 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Pharmicell. It details the date, location, and agenda items (financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation or notice of meeting sent to shareholders to inform them of upcoming voting matters, which falls under the Proxy Solicitation & Information Statement category.
2024-02-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.